Neogenomics, Inc.
NEO
$7.88
-$0.10-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.22% | -45.98% | -32.46% | 7.89% | 10.51% |
| Total Depreciation and Amortization | -6.51% | -4.27% | -2.34% | -1.38% | -0.05% |
| Total Amortization of Deferred Charges | -31.47% | -19.21% | -6.91% | 1.32% | 1.32% |
| Total Other Non-Cash Items | 75.98% | 80.15% | 62.83% | 17.47% | 19.05% |
| Change in Net Operating Assets | 1.64% | 17.64% | 40.17% | 23.05% | -28.00% |
| Cash from Operations | -25.53% | -8.80% | 5,221.59% | 150.15% | 459.60% |
| Capital Expenditure | 34.22% | 15.84% | -10.76% | -63.77% | -42.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.65% | -64.33% | -72.76% | -54.44% | -48.87% |
| Cash from Investing | -195.96% | -132.37% | -124.62% | -97.20% | -83.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -5,031,150.00% | -2,236,011.11% | -- | -- |
| Issuance of Common Stock | -74.52% | -31.02% | -28.70% | 25.64% | 12.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -39.47% | -50.90% | -39.47% | -39.47% |
| Cash from Financing | -4,410.98% | -3,925.44% | -3,487.41% | 19.74% | 2.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -945.68% | -454.91% | -403.53% | -74.64% | -69.08% |